Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like same numbers as last review, good to hear!
I agree on the data, but the change in enthusiasm brings back bad memories...I hope we get a more positive review in Q3.
Oren, doesn’t this Dsmc PR sound just like the one they released in the fall of 2017 for rgbm? Maybe that is partially the reason for the drop...
Biggest volume I’ve seen on this stock and it is in the red...disappointing
Oren-this silence seems eerily familiar. You think we will hear anything before December?
Where did u see this?
Not sure. Maybe speculation they will announce that the investigator led trial will begin soon to re-tri VB-111 in rgbm
Holy shit, didn’t think it would go this low...wtf
I think we will hear more before end of year, on the investigator led rgbm -reboot.
“Therefore, in addition to the ongoing OVAL trial we are exploring opportunities for investigator initiated trials of VB-111 in GBM and other oncology indications. We will elaborate on that in due time.”
Guess that answers my questions. Good to hear.
If they are so sure the reason of failure is not priming with VB111 before administering avastin, why not re try phase 3?
This toilet doesn’t stop flushing.
Oren, what would the next step be? Could they still get it approved for rgbm?
SNO conference next week. Supposed to present findings from phase 3 rgbm vb111 failure...according to Q2 earnings call...
I guess people were expecting more than lab rat results today...
Wow, just wasting away...
Anyone care to speculate on what happens next with rgbm and vb111?
Would they re-do phase 3? Attempt to get it approved with the full analysis?
What I don’t get is what happens next with rgbm? Do we redo phase 3?
Well Oren, you were right about the phase 3, dosing avastin first seems to be the reason for failur. Guess we will know more in november
They just emailed me back saying they will release date for earnings call soon and that they regularly post updates on their website...
I’ve emailed IR 3 times, since April, with no response...
Maybe they won’t release it because it will send the stock further down. Only want to discuss a failure once...
What happened to the analysis of the p3? Dror said it was “reasonable” to expect full results analysis in June...now it’s almost August.
How does a board member resigning make this go up 10%???
Nothing new from ASCO?
I haven’t taken the loss yet...maybe I should just get it over with...
Seems like this is going nowhere unless A) someone buys them B) ovarian does well C) go broke...
Well, their government still believes in them...
what should we be expecting from the analysis of the phase 3 data? What positives could we see? Negatives?
Any chance for fda approval if data shows that treating both arms with avastin is the reason for failure?
Sorry man, I haven’t yet, but I have mentally written this off
Thanks, I appreciate the feedback. This may be a dumb question, but in your experience has a drug ever been approved that did not meet primary endpoint? For the specific ailment it is treating?
Great maybe earnings will save us next week! Motherfu@ker! Now I’m stuck, sell now or sell when it drops further? Or will it rebound a bit? Anyone other than some smart ass douche bag have any advice?
Well that stung...
Probably, but not sure. Could be any day really, they just said Q1 2018. Most are predicting/hoping the results are positive. I for one am hoping they are...
Phase III trial results before end of month, he is just messing with u.
Read the previous press releases to catch up.
Just my opinion, but I believe they are operating “business as usual”. Meaning they will need money to grow the business and are not banking on a buyout. I don’t think this is negative, just SOP.
To build a factory and create supply for the imminent demand, u need options to get cash. This is one of those options...
What’s your take on this? I thought Avastin was already approved and was the standard of treatment.
Oren- what do you make of this? Is this why the stock dropped today?
http://www.businesswire.com/news/home/20171205006443/en/FDA-Grants-Genentech’s-Avastin-Full-Approval-Aggressive
That's what I understood. Slow start... everyone is waiting on phase 3 interim data...
Yeah maybe they dumped some shares yesterday. I remember seeing the filing where they acquired shares from a bad debt... hope that was all.